Alzheimer’s Disease (AD) is the most common form of dementia.Even
though this disease is affecting a large portion of the world’s population but
till now, there is no cure for it and every time a new treatment that comes up,
has failed to produce effective results in the various clinical trials.
Recently, a start-up company T3D Therapeutics mentioned that the failure of all
these drugs and treatments is because they failed to address the various
Alzheimer’s pathologies adequately. The most plausible reason behind this
disease is believed to be the insulin resistance in brain cells which causes
various adverse effects like: glucose
imbalance, insulin imbalance and beta amyloid plaque buildup etc. Which could be potential trigger for AD.
Multiple-potency mechanism of
T3D-959.
Most medicines and treatments that have been
developed and tested, focus only on one these abnormalities at a time. T3D
claims to have designed a drug that will be able to treat most of these
abnormalities at once., which would indeed increase the chances of successful
results. According to the company website, this medicine operates by acting as
an insulin sensitizer, down-regulating BACE expression, up-regulating
beta-amyloid degrading enzymes, down-regulating tau phosphorylation,
suppressing microglial production of alpha-beta-elicited inflammatory
mediators, blocking alpha-beta-peptide induced cell death, and increasing
acetylcholine production. The company also suggests that their drug would have
therapeutic effects on patients suffering from other central nervous system
disorders like Parkinson’s Disease, Multiple sclerosis, stroke and spinal cord
injuries. If this drugs go through all the clinical trials successful, where
all others have failed, then it would bring a revolution in the medical filed
and would save many lives across the globe.
